生产企业：Aldeyra Therapeutics
Reproxalap (previously ADX 102 or NS-2) is a small molecule inhibitor being developed by Aldeyra Therapeutics investigated against dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson syndrome. NS-2 has orphan drug status due to it being investigated for treatment of Sjogren-Larsson syndrome. In March 2026, the FDA issued a Complete Response Letter rejecting reproxalap, determining that clinical results were inconsistent and that positive findings were neither reliable nor meaningful.
Reproxalap (previously ADX 102 or NS-2) is a small molecule inhibitor being developed by Aldeyra Therapeutics investigated against dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson syndrome. NS-2 has orphan drug status due to it being investigated for treatment of Sjogren-Larsson syndrome. In March 2026, the FDA issued a Complete Response Letter rejecting reproxalap, determining that clinical results were inconsistent and that positive findings were neither reliable nor meaningful.
Reproxalap inhibits Reactive Aldehyde Species (RASP) and is being investigated against dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson syndrome.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
